Kite Pharma (Gilead Sciences)
Kite Pharma, a wholly owned subsidiary of Gilead Sciences, is the undisputed global leader in CAR-T cell therapy commercialization. Its flagship product Yescarta generated $1.5 billion in 2025 revenue, while Tecartus contributed $344 million. Kite operates four wholly-owned GMP-certified cell therapy manufacturing facilities across the United States and Europe, achieving a remarkable 14-day vein-to-vein turnaround time.
Strengths: Largest dedicated CAR-T manufacturing infrastructure worldwide; FDA removal of REMS requirements expanding community hospital access; strategic partnership with Cytiva for Sefia automated production platform; proven commercial execution with blockbuster Yescarta franchise; deep clinical expertise across multiple lymphoma indications.
Weaknesses: Significant Q4 2025 sales decline of 6% due to intensified competition from BMS Breyanzi; over-reliance on CD19-targeted CAR-T with limited pipeline diversification into other targets or indications; high operational costs from maintaining multiple large-scale manufacturing facilities.Read More ▼Show Less ▲
Strengths: Largest dedicated CAR-T manufacturing infrastructure worldwide; FDA removal of REMS requirements expanding community hospital access; strategic partnership with Cytiva for Sefia automated production platform; proven commercial execution with blockbuster Yescarta franchise; deep clinical expertise across multiple lymphoma indications.
Weaknesses: Significant Q4 2025 sales decline of 6% due to intensified competition from BMS Breyanzi; over-reliance on CD19-targeted CAR-T with limited pipeline diversification into other targets or indications; high operational costs from maintaining multiple large-scale manufacturing facilities.
Listed market data
GILD · NASDAQ · weeklyHistory →- Market cap
- $194 B
- Share price
- USD 156.19
- 1Y change
- +27.2%
- Recent change
- -0.7%
- Since first close
- ×241
- Revenue (TTM)
- $30.4 B
10-22 → 10-23
from 1992-01
Financial history
Full market history- 2026-10USD 156.19$194 B+4.8%
- 2026-09USD 149.05$185 B+1.9%
- 2026-08USD 146.34$182 B+12.4%
- 2026-07USD 130.21$162 B+3.1%
- 2026-06USD 126.34$157 B-6.0%
- 2026-05USD 134.43$167 B+2.7%
- 2026-04USD 130.84$162 B-6.1%
- 2026-03USD 139.37$173 B-6.4%
- 2026-02USD 148.95$185 B+4.9%
- 2026-01USD 141.95$176 B+15.7%
- 2025-12USD 122.74$152 B-2.5%
- 2025-11USD 125.84$156 B—
In the press
All coverage →5 latest headlines3- Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?trefis.com2026-10-17
- Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyoutsstocktwits.com2026-10-16
- Gilead Sciences (GILD) Rises Higher Than Market: Key Factsfinance.yahoo.com2026-10-15
- Gilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear.finance.yahoo.com2026-10-15
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026finance.yahoo.com2026-10-15
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $29.4 B | $8.5 B |
| 2024 | $28.8 B | $480 M |
| 2023 | $27.1 B | $5.7 B |
| 2022 | $27.3 B | $4.6 B |
| 2021 | $27.3 B | $6.2 B |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Santa Monica, California, United States
Founded
2009
Employees
2,000+ (Kite) / 18,000+ (Gilead)
Revenue
$1.8B (CGT product sales, 2025)
Market cap
$194 B
Factories
4 proprietary cell therapy super-factories (El Segundo CA, Frederick MD, Oceanside CA, Amsterdam NL)
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NASDAQ: GILD , Gilead Sciences 2025 Annual Report | Kite Pharma Global Manufacturing Locations | Kite Pharma — Wikipedia | CGTLive: CAR-T Manufacturing Efficiency Analysis